Q-omics provides the consensus-scored MT1XP1 profile across patient tissues and cancer cell-line models. MT1XP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MT1XP1 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, MT1XP1 RNA expression shows 13,848 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where MT1XP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT1XP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT1XP1 survival associations across molecular data types. MT1XP1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT1XP1 RNA expression–survival associations across cancer types. High MT1XP1 expression shows unfavorable associations in KIRC, HNSC, ACC, KIRP, COAD and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MT1XP1 RNA expression.
This table summarizes MT1XP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MT1XP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT1XP1 shows lower tumor expression in KIRP, KICH, THCA, LIHC and BRCA and higher tumor expression in UCEC. The KIRP box plot shows higher MT1XP1 RNA expression in normal versus tumor tissue (log2 FC = −1.647, t-test p < 0.001).
This table shows molecular features associated with MT1XP1 in patient tissues and cancer cell lines. In patient samples, MT1XP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
